Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta‐analysis

Myneedu, Kanchana; Deoker, Abhizith; Schmulson, Max; Bashashati, Mohammad

doi:10.1177/2050640619866990

Cited by 65 publications

(61 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, a significant improvement in IBS symptom scores was observed at three months favoring the placebo (p = 0.012), and after three months, the results obtained by an IBS quality of life questionnaire were in favor of the placebo (p = 0.003) [83]. Moreover, a recent meta-analysis including eight single-arm trials (SATs) and 5 RCTs did not report beneficial effects of FMT among patients with IBS (relative risk = 0.93, 95%, confidence interval (CI (confidence interval) 0.50-1.75, p = 0.83 for RCT), while in the SAT 59.5% of patients (95% CI 49.1-69.3) showed a significant improvement [84]. Given the controversies regarding the published data, FMT-based treatments for IBS are still not widely accepted among gastroenterologists, as they are concerned about effectiveness and safety profile [85].…”

Section: Fecal Microbiota Transplantationmentioning

confidence: 96%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

show abstract

Section: Fecal Microbiota Transplantationmentioning

confidence: 96%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“… 16 The mode of delivery may be a key issue, as classic FMT shows promise, while capsule delivery does not. 17 In order to understand this observed variability, it is necessary to characterize the intervention of classic FMT in detail.…”

Section: Introductionmentioning

confidence: 99%

Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome

et al. 2020

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common disorder of the lower gastrointestinal tract. The pathophysiology is far from settled, but a gut microbial dysbiosis is hypothesized to be a contributing factor. We earlier published a randomized double-blind placebo-controlled clinical trial on fecal microbiota transplantation (FMT) for IBS – the REFIT trial. The present data set describes the engraftment and includes participants from the study who received active FMT; 14 participants with effect of FMT ( Effect ) and 8 without ( No effect ). Samples were collected at baseline, after 6 and 12 months. Samples from the transplants ( Donor ) served as a comparator. In total 66 recipient samples and 17 donor samples were subjected to deep metagenomic sequencing, and taxonomic and functional analyses were performed. Alpha diversity measures showed a significantly increased diversity and evenness in the IBS groups compared to the donors. Taxonomic profiles showed higher relative abundance of phylum Firmicutes, and lower relative abundance of phylum Bacteroidetes, compared to donors at baseline. This profile was shifted toward the donor profile following FMT. Imputed growth rates showed that the resulting growth pattern was a conglomerate of donor and recipient activity. Thirty-four functional subclasses showed distinct differences between baseline samples and donors, most of which were shifted toward a donor-like profile after FMT. All of these changes were less pronounced in the No effect group. We conclude that FMT induces long-term changes in gut microbiota, and these changes mirror the clinical effect of the treatment. The study was registered in ClinicalTrials.gov (NCT02154867).

show abstract

“…En relación con el SII se han publicado tres metaanálisis que han evaluado el TMF como tratamiento. El primero de ellos, realizado por Myneedu, et al 54 , incluyó ocho estudios no controlados que sumaban 90 sujetos y cinco ensayos controlados aleatorizados con 151 pacientes y 105 controles. Si bien los en los estudios no controlados se observó mejoría clínica, en los ensayos controlados aleatorizados las diferencias no fueron significativas, por lo que los autores concluyen que el TMF no fue efectivo como tratamiento del SII.…”

Section: Trasplante De Microbiota Fecalunclassified

“…Es importante recalcar que los tres metaanálisis reportaron dificultades para la elaboración debido a la heterogeneidad de los artículos incluidos. Las diferentes vías de administración (cápsulas, sonda nasoyeyunal o colonoscopía), así como la falta de una diferenciación clara de varios de los artículos incluidos en relación con el subtipo de SII de los pacientes estudiados, impiden establecer conclusiones categóricas, y son necesarios más ensayos con protocolos específicos para futuros análisis [54][55][56] .…”

Section: Trasplante De Microbiota Fecalunclassified

Microbiota intestinal y estreñimiento. Una puesta al día

Hanna-Jairala¹,

Bustos-Fernández²

2021

NGL

View full text Add to dashboard Cite

Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta‐analysis

Cited by 65 publications

References 45 publications

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome

Microbiota intestinal y estreñimiento. Una puesta al día

Contact Info

Product

Resources

About